论文部分内容阅读
前列腺特异性膜抗原(PSMA)是一种2型跨膜糖蛋白,它特异性地表达于前列腺上皮细胞,是一种前列腺特异性标志物。PSMA在前列腺癌组织中的表达显著上调,且其表达水平与肿瘤的恶性程度及患者的生存密切相关。此外,PSMA也特异性地表达于多种肿瘤的新生血管内皮细胞。这些特点使得PSMA成为一种理想的肿瘤治疗靶点,以PSMA为靶点的肿瘤靶向治疗研究发展迅速,其中基于抗体的抗肿瘤策略如抗体偶联药物、免疫细胞治疗及免疫放射治疗等取得了显著的进展,证实了PSMA作为抗肿瘤靶点的可行性和有效性。本文就PSMA的结构和功能及针对PSMA的基于抗体的抗肿瘤治疗策略进行了总结。
Prostate-specific membrane antigen (PSMA) is a type 2 transmembrane glycoprotein that is specifically expressed on prostate epithelial cells and is a prostate-specific marker. The expression of PSMA in prostate cancer tissues was significantly up-regulated, and the expression level of PSMA was closely related to the malignancy and survival of patients. In addition, PSMA is also specifically expressed in neovascular endothelial cells of various tumors. These features make PSMA an ideal target for tumor therapy. Targeted tumor targeting therapy with PSMA has been rapidly developed. Antibody-based antitumor strategies such as antibody-coupled drugs, immune cell therapy and immunoradiotherapy have been developed Significant progress was made, confirming the feasibility and effectiveness of PSMA as an anti-tumor target. This article summarizes the structure and function of PSMA and the antibody-based antitumor treatment strategy for PSMA.